Medical Vertical Strong Growth
Medical sales of $96.0M in Q2, up 15% year-over-year and representing 28% of company sales; fourth consecutive quarter of YoY revenue growth in Medical with growth driven by Poland and Thailand and balanced contributions across North America, Europe and Asia.
Raised Full-Year Guidance
Fiscal 2026 net sales guidance raised to $1.40B–$1.46B (prior: $1.35B–$1.45B) driven by Medical strength and Automotive program ramps in Europe; adjusted operating income guidance increased to 4.2%–4.5% of net sales (prior: 4.0%–4.25%).
Gross Margin and Operating Margin Improvement
Q2 gross margin rate improved to 8.2% from 6.6% in prior-year period, a +160 basis point improvement; adjusted operating income of $15.3M, or 4.5% of net sales, versus $13.3M or 3.7% last year.
Positive Operating Cash Flow and Strong Liquidity
Operating cash flow in Q2 was $6.9M — the eighth consecutive quarter of positive cash from operations. Cash and cash equivalents of $77.9M and combined short-term liquidity (cash + unused credit) of $363M at quarter end.
Lower Interest Expense and Reduced Debt
Other expense improved to $3.8M from $4.8M a year ago with interest expense down ~50% YoY. Total borrowings of $154M were down ~$51M (~25%) compared to a year ago.
Inventory and Working Capital Progress
Inventory decreased to $281.7M, down $24.5M (8%) year-over-year. Cash conversion days were 91 days, a 16-day improvement versus Q2 FY25 despite an 8-day increase from the prior quarter; management expects continuing focus and improvement.
Strategic Investments and New CMO Capacity
Grand opening of a 300,000 sq ft medical CMO facility in Indianapolis (adds U.S. capacity for single-use surgical instruments, drug delivery devices and plastic injection molding). Company is rebranding to "Kimball Solutions" to reflect expanded capabilities and pursuing disciplined M&A to expand customers and capabilities.
Shareholder Returns
Repurchased $4.3M of stock in Q2 (149,000 shares); since program inception $109.5M returned to shareholders (6.8M shares) with $10.5M remaining on the repurchase authorization.